Andreassen, OA, Harbo, HF, Wang, Y, et al. (2015) Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Molecular Psychiatry, 20: 207–14.
Bamer, AM, Cetin, K, Johnson, KL, et al. (2008) Validation study of prevalence and correlates of depressive symptomatology in multiple sclerosis. General Hospital Psychiatry, 30: 311–7.
Benedict, RH, Munschauer, F, Zarevics, P, et al. (2008) Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients. Journal of Neurology, 255: 848–52.
Benros, ME, Eaton, WW, Mortensen, PB (2014) The epidemiologic evidence linking autoimmune diseases and psychosis. Biological Psychiatry, 75: 300–6.
Chiaravalloti, ND, Genova, HM, DeLuca, J (2015) Cognitive rehabilitation in multiple sclerosis: the role of plasticity. Frontiers in Neurology, 6: 67.
Cotter, J, Firth, J, Enzinger, C (2016) Social cognition in multiple sclerosis: a systematic review and meta-analysis. Neurology, 87: 1727–36.
Cottrell, S, Wilson, S (1926) The affective symptomatology of disseminated sclerosis: a study of 100 cases. Journal of Neurological Psychopathology, 7: 1–30.
Ensari, I, Motl, RW, McAuley, E, et al. (2014) Patterns and predictors of naturally occurring change in depressive symptoms over a 30-month period in multiple sclerosis. Multiple Sclerosis, 20: 602–9.
Feinstein, A (2002) An examination of suicidal intent in patients with multiple sclerosis. Neurology, 59: 674–8.
Feinstein, A, Banwell, E, Pavisian, B (2015) What to make of cannabis and cognition in MS: in search of clarity amidst the haze. Multiple Sclerosis Journal, 21: 1755–60.
Feinstein, A, du Boulay, G, Ron, MA (1992) Psychotic illness in multiple sclerosis: a clinical and magnetic resonance imaging study. British Journal of Psychiatry, 161: 680–5.
Feinstein, A, Magalhaes, S, Richard, JF, et al. (2014) The link between multiple sclerosis and depression. Nature Reviews, Neurology, 10: 507–17.
Feinstein, A, O'Connor, P, Akbar, N, et al. (2010) Diffusion tensor imaging abnormalities in depressed multiple sclerosis patients. Multiple Sclerosis, 16: 189–96.
Fernie, BA, Kollmann, J, Brown, RG (2015) Cognitive behavioural interventions for depression in chronic neurological conditions: a systematic review. Journal of Psychosomatic Research, 78: 411–9.
Fiest, KM, Walker, JR, Bernstein, CN, et al. (2016) Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Multiple Sclerosis and Related Disorders, 5: 12–26.
Foong, J, Rozewicz, L, Quaghebeur, G, et al. (1997) Executive function in multiple sclerosis. The role of frontal lobe pathology. Brain, 120: 15–26.
Gobbi, C, Rocca, MA, Riccitelli, G, et al. (2014) Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis. Multiple Sclerosis, 20: 192–201.
Gold, S, Kern, K, O'Connor, M (2010) Smaller cornu ammonis, 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biological Psychiatry, 68: 553–9.
Harel, Y, Appleboim, N, Lavie, M, et al. (2009) Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. Journal of Neurological Sciences, 276: 38–40.
Hulst, HE, Goldschmidt, T, Nitsche, MA, et al. (2017) rTMS affects working memory performance, brain activation and functional connectivity in patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 88: 386–94.
Lacy, M, Hauser, M, Pliskin, N, et al. (2013) The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Multiple Sclerosis, 19: 1765–72.
Marrie, RA, Cohen, J, Stuve, O, et al. (2015) A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Multiple Sclerosis, 21: 263–81.
Minden, SL, Feinstein, A, Kalb, RC, et al. (2014) Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 82: 174–81.
Mohr, DC, Hart, SL, Fonareva, I, et al. (2006) Treatment of depression in patients with multiple sclerosis in neurological clinics. Multiple Sclerosis, 12: 204–8.
Morrow, SA, Smerbeck, A, Patrick, K, et al. (2013) Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study. Journal of Neurology, 260: 489–97.
Muhlert, N, Sethi, V, Schneider, T, et al. (2013) Diffusion MRI-based cortical complexity alterations associated with executive function in multiple sclerosis. Journal of Magnetic Resonance Imaging, 38: 54–63.
Muhlert, N, Sethi, V, Cipolotti, L, et al. (2015) The grey matter correlates of impaired decision making in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 86: 530–6.
Nigro, S, Passamonti, L, Riccelli, R, et al. (2015) Structural ‘connectomic’ alterations in the limbic system of multiple sclerosis patients with major depression. Multiple Sclerosis, 21: 1003–12.
Nygaard, G, Walhovd, K, Sowa, P (2015) Cortical thickness and surface area relate to specific symptoms in early relapsing-remitting multiple sclerosis. Multiple Sclerosis, 21: 402–14.
O'Brien, A, Chiaravalloti, N, Goverover, Y, et al. (2008) Evidence-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Archives of Physical Medicine and Rehabilitation, 89: 761–9.
Passamonti, L, Cerasa, A, Liguori, M, et al. (2009) Neurobiological mechanisms underlying emotional processing in relapsing-remitting multiple sclerosis. Brain, 132: 3380–91.
Patten, S, Svenson, L, Metz, L (2005) Psychotic disorders in MS: population-based evidence of an association. Neurology, 65: 1123–5.
Patti, F, Amato, M, Bastianello, S, et al. (2009) Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing remitting multiple sclerosis: 2-years results from the COGIMUS study. Therapeutic Advances in Neurological Disorder, 2: 67–77.
Pioro, EP (2014) Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA®) for pseudobulbar affect, Neurology and Therapy, 3: 15–28.
Price, A, Rayner, L, Okon-Rocha, E, et al. (2011) Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomized control trials. Journal of Neurology, Neurosurgery and Psychiatry, 82: 914–23.
Rocca, MA, Pravatà, E, Valsasina, P, et al. (2015) Hippocampal-DMN disconnectivity in MS is related to WM lesions and depression. Human Brain Mapping, 36: 5051–63.
Scalfari, A, Knappertz, V, Cutter, G, et al. (2013) Mortality in patients with multiple sclerosis. Neurology, 81: 184–92.
Solomon, A, Weinshenker, B (2013) Misdiagnosis of multiple sclerosis: frequency, causes, effects, and prevention. Current Neurology and Neuroscience Reports, 13: 403.
Strober, LB, Arnett, PA (2010) Assessment of depression in multiple sclerosis: development of a “trunk and branch” model. Clinical Neuropsycholy, 24: 1146–66.
Sumowski, JF, Wylie, GR, Deluca, J, et al. (2010) Intellectual enrichment is linked to cerebral efficiency in multiple sclerosis: functional magnetic resonance imaging evidence for cognitive reserve. Brain, 133: 362–74.
Titulaer, MJ, Höftberger, R, Iizuka, T, et al. (2014) Overlapping demyelinating syndromes and anti–N-methyl-d-aspartate receptor encephalitis. Annals of Neurology, 75: 411–28.
Weinstock-Guttman, B, Galetta, SL, Giovannoni, G, et al. (2012) Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology, 259: 898–905.